References
- American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2)596–601
- American Medical Association. Expert Committee Recommendations on the Assessment, Prevention, and Treatment of Child and Adolescent Overweight and Obesity recommendations for treatment of pediatric obesity, http://www.ama-assn.org/ama/pub/category/11759.html. Accessed 25 November 2007
- Borai A, Livingstone C, Ferns GA. The biochemical assessment of insulin resistance. Annals of Clinical Biochemistry 2007; 44(4)324–342
- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 2006; 3(2)A42
- Correll CU. Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectrums 2007; 12((10) (Suppl. 17))12–20, 35
- Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 48: 9–20
- Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 771–791
- Correll CU, Nyilas M, Aurang C, et al. Safety and tolerability of aripiprazole in children with mania. Poster presented at the 54th American Academy of Child and Adolescent Psychiatry Meeting. Boston, MAUSA 23–28 October, 2007
- Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinic of North America 2006; 15: 177–206
- Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. New England Journal of Medicine 2005; 352: 2100–2109
- Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: Public-health crisis, common sense cure. Lancet 2002; 360(9331)473–482
- Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Systematic Review 2007; 1: CD005148
- Fernandez JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. Journal of Pediatrics 2004; 145: 439–444
- Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among US adolescents: A population-based study. Diabetes Care 2006; 29: 2427–2432
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–576
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005; 19(Suppl. 1)1–93
- Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. American Journal of Psychiatry 2007; 164(9)1404–1410
- Yeckel CW, Weiss R, Dziura J, et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. Journal of Clinical Endocrinology and Metabolism 2004; 89(3)1096–1101